Skip to content
Evolving Treatment Landscape for Mantle Cell Lymphoma (MCL) in Canada – Video Series
We hope you found the content valuable; your feedback is very important to us and we appreciate you taking the time to complete this evaluation form.
1.
Profession
Physician
Nurse
Pharmacist
Social worker or case manager
Other (please specify)
2.
How relevant was this learning program to your practice/role?
Not applicable
Not at all relevant
Slightly relevant
Moderately relevant
Very relevant
Extremely relevant
3.
Overall, how satisfied are you with the quality of the learning content?
Not applicable
Not at all satisfied
Slightly satisfied
Moderately satisfied
Very satisfied
Extremely satisfied
4.
How satisfied are you that the learning objectives were achieved?
Learning objectives for this program included:
1. Review emerging first-line and relapsed/refractory treatment options for MCL in Canada.
2. Assess the impact of novel therapies on treatment sequencing and patient selection for CAR T-cell therapy.
3. Contextualize the role of CAR T-cell therapy within the rapidly evolving therapeutic landscape of relapsed/refractory MCL.
Not applicable
Not at all satisfied
Slightly satisfied
Moderately satisfied
Very satisfied
Extremely satisfied
5.
How will the learning content support your practice?
My current practice has been reinforced by this learning content
I plan to use the new concepts learned in this program in my practice
I may improve my practice, but I need additional information to support this learning content
Not applicable
If you selected “I may improve my practice...”, please describe what additional information is needed to support this learning content.
